This CAR T-cell therapy has revolutionized the management of high-risk and relapsed or refractory disease.
Jordan D. Scott, PharmD
Advertisement
Articles by Jordan D. Scott, PharmD
An interdisciplinary discussion addresses the disparity in availability and use of these therapies across the continuum of care.
Advertisement
Latest Updated Articles
Operationalizing Bispecific Antibodies Across Academic and Community Oncology Centers in Hematologic MalignanciesPublished: June 25th 2024 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Addressing Drug Resistance in Lung Cancer
2
Final EMBARK Data Show “Almost Unprecedented” Reduction in Risk of Death With Enzalutamide Plus ADT in Biochemically Recurrent Prostate Cancer
3
From Mutation to Medicine: Targeted Therapies in Lung Cancer
4
Tar-200 Plus Anti–PD-1 Therapy Shows Promising Neoadjuvant Activity in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
5
